Omega Fund Management
Boston, MAfiles as Omega Fund Management, LLC
$186m in 10 US stocks at the end of 30 June 2026. The top 10 are 100.0% of the money. It changed about 8.6% of the portfolio this quarter.
Value
$186m
Stocks
10
Top 10 share
100.0%
Turnover
8.6%
What changed this quarter
New
Bought for the first time this quarter.
- Odyssey TherapeuticsODTX<0.1% of the fund
Added
Bought more of a stock they already held.
None this quarter.
Cut
Sold some of their stake.
- Bicara TherapeuticsBCAX29.1% of the fund-24%
Sold out
Sold their entire stake.
- Replimune GroupREPL-100%
Holdings
- Engene Holdings
- Share
- 0.8%
- Value
- $2m
- Shares
- 876,357
Held
- Odyssey TherapeuticsODTX
- Share
- <0.1%
- Value
- $54,128
- Shares
- 2,893
New
| Company | Share of fund | Value | Shares | Change |
|---|---|---|---|---|
| Bicara TherapeuticsBCAX | 29.1% | $54m | 1,822,150 | -24% |
| Nuvation BioNUVB | 24.7% | $46m | 8,081,089 | Held |
| Kestra Medical TechnologiesKMTS | 14.0% | $26m | 1,022,149 | Held |
| BridgeBio Oncology TherapeuticsBBOT | 13.5% | $25m | 3,289,661 | Held |
| Beta BionicsBBNX | 11.1% | $21m | 1,316,183 | Held |
| AlumisALMS | 3.7% | $7m | 241,255 | Held |
| Sana BiotechnologySANA | 1.6% | $3m | 843,750 | Held |
| ImageneBioIMA | 1.4% | $3m | 455,361 | Held |
| Engene Holdings | 0.8% | $2m | 876,357 | Held |
| Odyssey TherapeuticsODTX | <0.1% | $54,128 | 2,893 | New |
Over time and by industry
Value over time
Jun '25
Dec '25
Jun '26
Value is up 20.2% since 30 June 2025.
Where the money is
Health care99.2%
Other0.8%
From the fund's 13F filings. They list US stocks and options only, 45 days after each quarter, and leave out cash, bonds, shorts and foreign shares.